newsfilter
← Latest News
PR Newswire·

FibroBiologics Announces Australian Patent Accepted for Cannabidiol Adjuvant Therapy for the Treatment of Degenerative Disc Disease

FBLG
  • FibroBiologics, Inc. received acceptance from IP Australia for Australian Patent Application No. 2020368344 covering cannabidiol adjuvant therapy for degenerative disc disease.
  • The patent describes methods to treat degenerative disc disease by administering cannabidiol alongside a therapeutically effective amount of fibroblast cells.
  • The application claims the use of cannabidiol to reduce apoptosis in disc cells, create a favorable environment for regeneration, & augment fibroblast regenerative activity.
  • Cannabidiol is intended to enhance the production of growth factors such as IGF-1 & EGF-1 by fibroblasts.
  • Fibroblast-based cell therapy involves differentiating fibroblasts into notochord cells or chondrocytes to replenish the nucleus pulposus.
  • Cannabidiol may be administered systemically, transdermally, or directly into the disc.
  • CEO Pete O'Heeron stated the combination aims to protect disc cells while promoting regeneration rather than just managing symptoms.
  • FibroBiologics currently holds over 270 issued & pending patents across various clinical pathways including wound healing, multiple sclerosis, & cancer.
  • The company is based in Houston & focuses on developing therapeutics using fibroblasts & fibroblast-derived materials for chronic diseases.